Brody's Human Pharmacology, 7th Edition
By Lynn Wecker, Susan L. Ingram
TU
TO
R
G
U
R
U
, Table of Content
Part I: General Principles, Lynn Wecker
1 Pharmacodynamics: Receptors and Concentration-Response Relationships
2 Pharmacokinetics: Absorption, Distribution, Metabolism and Elimination
3 Clinical Pharmacokinetics and Issues in Therapeutics
4 Drug Development, Regulation and Prescription Writing
5 Gene Therapy and Emerging Molecular Therapies
6 Antibodies and Biological Products
7 Herbals and Natural Products
8 Principles of Toxicology
TU
Part II: Drugs Affecting the Peripheral Nervous System, Skeletal and Smooth Muscle,
Carl Faingold
9 Introduction to the Autonomic Nervous System
10 Drugs Affecting the Parasympathetic Nervous System and Autonomic Ganglia
11 Drugs Affecting the Sympathetic Nervous System
TO
12 Skeletal Muscle Relaxants
13 Local Anesthetics
14 Histamine and Antihistamines
15 Eicosanoids
R
16 Drugs to Treat Asthma and Chronic Obstructive Pulmonary Disease
17 Drugs Affecting Uterine Motility
G
18 Drugs Affecting the Gastrointestinal System
Part III: Drugs Affecting the Cardiovascular, Renal and Circulatory Systems, Stephanie
Watts
U
19 Introduction to the Regulation of Cardiovascular Function
20 Antihypertensive Drugs
R
21 Diuretic Drugs
22 Antiarrhythmic Drugs
23 Drugs to Treat Heart Failure
U
24 Vasodilators and Nitric Oxide Synthase
25 Lipid-Lowering Drugs and Atherosclerosis
26 Antithrombotic Drugs
Part IV: Drugs Affecting the Central Nervous System, Lynn Wecker
27 Introduction to the Central Nervous System
28 Treatment of Parkinson’s and Alzheimer's Diseases
29 Treatment of Psychotic Disorders
30 Treatment of Affective Disorders
31 Treatment of Anxiety and Insomnia
,32 Ethanol, Other Alcohols and Drugs for Alcohol Dependence
33 Treatment of Obesity and Eating Disorders
34 Treatment of Seizure Disorders
35 General Anesthetics
36 Drugs to Control Pain
37 Drugs and Substance Abuse, Addiction and Treatment
Part V: Drugs Affecting Endocrine Systems, George Dunaway
38 Introduction to Endocrine Pharmacology and Hormones of the Hypothalamus and Pituitary
Gland
39 Adrenocorticosteroids
40 Estrogens and Progestins
TU
41 Androgens and Antiandrogens
42 Thyroid and Antithyroid Drugs
43 Insulin and Drugs Used in the Therapy of Diabetes Mellitus
44 Calcium-Regulating Hormones and Other Agents Affecting Bone
TO
Part VI: Chemotherapy of Invading Organisms, Lynn Crespo
45 Principles of Antimicrobial Use
46 Bacterial Cell Wall Synthesis Inhibitors
47 Inhibitors of Bacterial Ribosomal Actions
R
48 Bacterial Folate Antagonists, Fluoroquinolones, and Other Antibacterial Agents
49 Antimycobacterial Agents
50 Antifungal Agents
G
51 Antiviral Agents
52 Drugs to Treat Parasitic Infections
U
Part VII: Chemotherapy of Neoplastic Diseases, Lynn Crespo
53 Principles of Antineoplastic Drug Use
54 Mechanisms of Action of Antineoplastic Drugs
R
55 Adjuvant Antineoplastic Drugs
U
, Wecker: Brody’s Human Pharmacology, 7th Edition
Chapter 01: Pharmacodynamics: Receptors and Concentration-Response Relationships
Test Bank
Multiple Choice
1. The majority of medications available today act on which superfamily of cellular
membrane receptor?
A. Ligand-gated ion channel
TU
B. G-protein-coupled receptor
C. Receptor tyrosine kinase
D. Nuclear hormone receptor
E. Cytokine receptor
ANS: B. The majority of drugs available act on G-protein-coupled receptors.
TO
2. Nalbuphine is an effective pain reliever because of its activity at mu-opioid receptors.
However, if given to a patient who has recently received morphine (which also affects
mu-opioid receptors) for postoperative pain, nalbuphine can worsen his or her pain. Thus
nalbuphine is said to have what kind of activity at mu-opioid receptors?
R
A. Full agonist
B. Partial agonist
C. Competitive antagonist
G
D. Non-competitive antagonist
E. Allosteric modifier
ANS: B. Nalbuphine is a partial agonist at opioid receptors.
U
R
U